Administering anti-CD53 IgG1 could lead to even more significant loss of non-tumor cells than CD52-targeting alemtuzumab, which is typically reserved for salvage therapy in CLL due to widespread CD52 expression among non-B leukocytes. This evidence concerns the gene CD52 and B-cell chronic lymphocytic leukemia.